Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

POLARIS: PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER: A PROSPECTIVE MULTICENTER NON-INTERVENTIONAL STUDY

X
Trial Profile

POLARIS: PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER: A PROSPECTIVE MULTICENTER NON-INTERVENTIONAL STUDY

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Aromatase inhibitors; Fulvestrant; Tamoxifen
  • Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms POLARIS
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Jun 2024 Results(N=1250) describing Real-world progression-free survival (rwPFS) and overall survival (OS) ,presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 24 Oct 2023 Results assessing real-world impact on outcomes in patients advanced breast cancer, presented at the 48th European Society for Medical Oncology Congress.
    • 24 Oct 2023 Results assessing impact of comorbidities on pt quality of life (QoL) using the EORTC-QLQ-C30 questionnaire. presented at the 48th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top